Cardio Diagnostics Publishes Novel And Scalable Pathways To Enhance Global Coronary Heart Disease Care through Precision Epigenetics In Epigenomics
Portfolio Pulse from Benzinga Newsdesk
Cardio Diagnostics Holdings, Inc (NASDAQ:CDIO) has published a peer-reviewed article outlining scalable pathways that leverage precision epigenetics to revolutionize coronary heart disease (CHD) care globally. The company's PrecisionCHD™ test uses digital PCR laboratory assays to quantify epigenetic signatures that are interpreted by artificial intelligence (AI) to determine the presence or absence of CHD. The test can be performed within hours using standard laboratory equipment.
September 20, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cardio Diagnostics' publication of a peer-reviewed article on precision epigenetics for CHD care could potentially boost the company's reputation in the medical field. The PrecisionCHD™ test, which uses AI to interpret epigenetic signatures, could revolutionize CHD care.
The publication of a peer-reviewed article is a significant achievement for any company, as it validates their research and development efforts. The PrecisionCHD™ test, which uses AI to interpret epigenetic signatures, could revolutionize CHD care, potentially leading to increased demand for Cardio Diagnostics' services and a positive impact on its stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100